NKG2A Is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple-Negative Breast Cancer.

Brandie C Taylor ,Elizabeth Wescott ,Ann Hanna ,Elizabeth Claire Dees ,Luc Van Kaer ,Payal D Shah ,Shu-Ting Chou ,Brian D Lehmann ,Susan R Opalenik ,Claudine Isaacs ,Melinda E Sanders ,Jennifer A Pietenpol ,Paula I Gonzalez-Ericsson ,Tarah J Ballinger ,Cesar Augusto Santa-Maria ,Xiaopeng Sun ,Vandana G Abramson ,Violeta Sanchez ,Henry Gómez ,Justin M Balko

doi:10.1158/2159-8290.cd-23-0519

NKG2A Is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple-Negative Breast Cancer.

Brandie C Taylor , Elizabeth Wescott + Show 18 more

Open Access

https://doi.org/10.1158/2159-8290.cd-23-0519

Copy DOI

Journal: Cancer Discovery	Publication Date: Oct 3, 2023
Citations: 2	License type: CC BY-NC-ND 4.0

Affiliation: Vanderbilt University Medical Center, Vanderbilt University, University of North Carolina at Chapel Hill, University of Pennsylvania, Georgetown University Medical Center, Georgetown University, Indiana University – Purdue University Indianapolis, Johns Hopkins University, Instituto Nacional de Enfermedades Neoplásicas

#Heterogeneous Triple Negative Breast Cancer #IFNγ Dependent Manner + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Clinical resistance to immunotherapy is common in breast cancer, and many patients will likely require combination therapy to maximize immunotherapeutic benefit. This study demonstrates that heterogeneous MHC-I expression drives resistance to anti-PD-L1 therapy and exposes NKG2A on NK cells as a target to overcome resistance. This article is featured in Selected Articles from This Issue, p. 201.

Full Text